These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3436486)

  • 1. Clinical use of controlled-release theophylline in chronic airways obstruction.
    Dal Negro R; Turco P; Pomari C; Cordaro CI
    J Int Med Res; 1987; 15(6):391-6. PubMed ID: 3436486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1982 Apr; 13(4):569-71. PubMed ID: 7066172
    [No Abstract]   [Full Text] [Related]  

  • 3. [Time-related distribution of delayed-action theophylline in the treatment of chronic obstructive bronchopneumopathies].
    Philip-Joet F; Bruguerolle B; Parrel M; Vestri R; Arnaud A
    Presse Med; 1988 Feb; 17(5):193-6. PubMed ID: 2965374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose response relation to oral theophylline in severe chronic obstructive airways disease.
    Chrystyn H; Mulley BA; Peake MD
    BMJ; 1988 Dec; 297(6662):1506-10. PubMed ID: 3147048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic obstructive pulmonary disease with two sustained-release theophylline preparations.
    Giosue S; Bernocchi D; Parola D; Munno R; Mancini P
    J Int Med Res; 1987; 15(6):352-60. PubMed ID: 3325318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effectiveness and safety of a controlled-release theophylline in patients with reversible and stable bronchial obstruction.
    Grassi V; Nicora M; Beretta A
    Int J Clin Pharmacol Res; 1987; 7(5):337-44. PubMed ID: 3667006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of theophylline in chronic obstructive lung disease.
    Umut S; Gemicioğlu B; Yildirim N; Barlas A; Ozüner Z
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):149-52. PubMed ID: 1592541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical functional study of a new delayed-action preparation of "once a day" anhydrous theophylline in patients with chronic obstructive bronchopneumopathy].
    Gatto PG; Bruzzoni A; Valenti V
    Clin Ter; 1989 Jul; 130(1):45-9. PubMed ID: 2529079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial.
    Melillo G; Balzano G; Jodice F; De Felice A; Campisi V; Capone M; Di Filippo A; Foddai G; Franzone JS; Grossi E
    Int J Clin Pharmacol Res; 1989; 9(6):397-405. PubMed ID: 2699466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of a new delayed-release anhydrous theophylline by single daily administration in the treatment of reversible bronchial obstruction. Comparison with a delayed-release preparation administered twice daily].
    Baronti A; Verdiani P; Di Carlo S
    Clin Ter; 1987 Sep; 122(6):437-40. PubMed ID: 2972456
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-daily dosing of a new ultrasustained-release theophylline preparation.
    Van den Brande P; Nys J; Tjandramaga TB; Verhelst F; Demedts M
    Respiration; 1987; 52(2):144-53. PubMed ID: 3671893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of sustained-release theophylline ('Theo-dur') for the treatment of chronic reversible obstructive lung disease in hospital practice.
    Riddington CJ; Shipman AJ
    Br J Clin Pract; 1985 Apr; 39(4):148-53. PubMed ID: 3893504
    [No Abstract]   [Full Text] [Related]  

  • 13. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.
    McKay SE; Howie CA; Thomson AH; Whiting B; Addis GJ
    Thorax; 1993 Mar; 48(3):227-32. PubMed ID: 8497820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease.
    Murciano D; Auclair MH; Pariente R; Aubier M
    N Engl J Med; 1989 Jun; 320(23):1521-5. PubMed ID: 2498658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease.
    Taylor DR; Duffin D; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1984 Jul; 18(1):27-30. PubMed ID: 6743488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of obstructive respiratory tract diseases with pure theophylline retard].
    Arens PJ
    Med Klin Prax; 1982 Aug; 77(18):48-53, 67. PubMed ID: 6752679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unequal twice-daily, sustained-release theophylline dosing in chronic obstructive pulmonary disease.
    Bruguerolle B; Philip-Joet F; Parrel M; Arnaud A
    Chronobiol Int; 1987; 4(3):381-5. PubMed ID: 3315267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slow release theophylline in patients with airways obstruction with particular reference to the effects of food upon serum levels.
    Thompson PJ; Kemp MW; McAllister WA; Turner-Warwick M
    Br J Dis Chest; 1983 Jul; 77(3):293-8. PubMed ID: 6351891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two sustained-release theophylline preparations in adult patients with obstructive airways disease.
    Harkaway PS; Conlon PF; Hirsh JD; Allen WT
    J Clin Pharmacol; 1985 Sep; 25(6):444-7. PubMed ID: 4056079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interactions of theophylline and nifedipine].
    Luther R; Wichert H; Köhler E; Banditt P; Walther H
    Z Erkr Atmungsorgane; 1990; 174(2):97-103. PubMed ID: 2349818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.